Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dose-response study with high-dose inhaled salmeterol in healthy subjects.

Literature DB >> 1349491

Dose-response study with high-dose inhaled salmeterol in healthy subjects.

Abstract

A double-blind, placebo-controlled, cross-over study in 10 healthy male subjects has been carried out to investigate the non-pulmonary effects of single inhaled doses of salmeterol 100 micrograms, 200 micrograms and 400 micrograms and salbutamol 400 micrograms from a metered-dose inhaler. At all doses tested, salmeterol produced statistically significant changes in pulse rate, tremor, blood glucose and plasma potassium concentrations, compared with placebo. All changes were dosed related. A number of dose-related adverse events including tremor, awareness of heart beat and headache were reported after salmeterol administration.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1992 PMID： 1349491 PMCID： PMC1381289 DOI： 10.1111/j.1365-2125.1992.tb04049.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

9 in total

1. Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers.

Authors: M Scheinin; M Koulu; E Laurikainen; H Allonen
Journal: Br J Clin Pharmacol Date: 1987-11 Impact factor: 4.335

2. Subsensitivity of beta-adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol.

Authors: B J Lipworth; R A Clark; D P Dhillon; D G McDevitt
Journal: Eur J Clin Pharmacol Date: 1990 Impact factor: 2.953

3. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline.

Authors: J Crane; C Burgess; R Beasley
Journal: Thorax Date: 1989-02 Impact factor: 9.139

4. Epinephrine-induced hypokalemia: relation to liver and skeletal muscle.

Authors: R L Vick; E P Todd; D W Luedke
Journal: J Pharmacol Exp Ther Date: 1972-04 Impact factor: 4.030

5. Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo.

Authors: T L Whitsett; C V Manion; M F Wilson
Journal: Br J Clin Pharmacol Date: 1981-08 Impact factor: 4.335

6. Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma.

Authors: B J Lipworth; R A Clark; D P Dhillon; R A Brown; D G McDevitt
Journal: Br J Clin Pharmacol Date: 1988-11 Impact factor: 4.335

7. Intracoronary injections of salbutamol demonstrate the presence of functional beta 2-adrenoceptors in the human heart.

Authors: J A Hall; M C Petch; M J Brown
Journal: Circ Res Date: 1989-09 Impact factor: 17.367

8. Effect of intravenous adrenaline on electrocardiogram, blood pressure, and serum potassium.

Authors: A D Struthers; J L Reid; R Whitesmith; J C Rodger
Journal: Br Heart J Date: 1983-01

9. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.

Authors: C S Wong; I D Pavord; J Williams; J R Britton; A E Tattersfield
Journal: Lancet Date: 1990-12-08 Impact factor: 79.321

9 in total

11 in total

Review 1. Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma.

Authors: J C Adkins; D McTavish
Journal: Drugs Date: 1997-08 Impact factor: 9.546

9. Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers.

Authors: S M Kirby; J Smith; G P Ventresca
Journal: Thorax Date: 1995-06 Impact factor: 9.139

10. Indacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist.

Authors: Jorge Roig; Rosana Hernando; Ramon Mora
Journal: Open Respir Med J Date: 2009-03-12

Dose-response study with high-dose inhaled salmeterol in healthy subjects.

1. Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers.

2. Subsensitivity of beta-adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol.

3. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline.

4. Epinephrine-induced hypokalemia: relation to liver and skeletal muscle.

5. Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo.

6. Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma.

7. Intracoronary injections of salbutamol demonstrate the presence of functional beta 2-adrenoceptors in the human heart.

8. Effect of intravenous adrenaline on electrocardiogram, blood pressure, and serum potassium.

9. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.

Review 1. Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma.

Review 2. Clinical pharmacokinetics of salmeterol.

Review 3. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.

4. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects.

5. Does tachyphylaxis occur to the non-pulmonary effects of salmeterol?

6. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.

7. Systemic effects of salbutamol and salmeterol in patients with asthma.

8. Short-term safety and tolerability of double-dose salmeterol/fluticasone propionate in adult asthmatic patients.

9. Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers.

10. Indacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist.